Browsing by Keywords "CpG ODN"
Now showing items 1-9 of 9
-
Development & characterization of CpG adjuvanted SARS-CoV-2 Virus-Like Particle vaccine
(Bilkent University, 2022-06)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in late 2019, led to countless cases and deaths and eventually regarded as one of the severe pandemics of modern times. To reduce hospitalization and ... -
Development of CpG ODN based vaccine adjuvant formulations
(Humana Press, New York, 2016) -
Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response
(Elsevier, 2020)Nucleic acid-based pattern recognition receptor agonists are effective adjuvants and immunotherapeutic agents. Rather than single applications, ligand combinations could synergistically potentiate immune responses by ... -
Elucidating immunomodulatory effects of telomeric repeat mimicking synthetic A151 oligodeoxynucleotide on immune cell transcriptome
(Bilkent University, 2019-09)Recent evidence revealed that DNA is beyond just the blueprint of life; it is also involved in immunomodulation. Unmethylated Cytosine-phosphate-Guanine (CpG) motifs of prokaryotic DNA stimulate immune response by ... -
Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG
(Wiley - V C H Verlag GmbH & Co. KGaA, 2015)Recognition of pathogen-derived nucleic acids by immune cells is critical for the activation of protective innate immune responses. Bacterial cyclic dinucleotides (CDNs) are small nucleic acids that are directly recognized ... -
In vivo applications of liposomal vaccines encapsulating single or dual pathogenassociated molecular patterns
(Bilkent University, 2017-03)Nucleic acid-based pattern recognition receptor (PRR) agonists are promising adjuvants and immunotherapeutic agents. Combination of PRR ligands potentiates immune response by providing synergistic immune activity via ... -
Investigation of Pre-clinical and clinical results against SARS-COV-2 wild-type and Alpha variants combination of VLP-58-1023-AL-K3 vaccine
(Bilkent University, 2022-08)The SARS-CoV-2 virus, which first appeared in Wuhan, China and had a pandemic effect at the end of 2019, has urgently created need of suitable vaccine candidates’ development with its quick spread. Scientists in different ... -
Investigation of Pre-clinical and Phase II clinical studies of VLP-58-1023- AL-K3-PII vaccine for Alpha variant
(Bilkent University, 2022-08)In the late December of 2019, SARS-CoV-2, a new coronavirus, was discovered in Wuhan, China and described as the causative agent of Coronavirus Disease 2019 (COVID-19). The disease has spread rapidly across the world due ... -
Liposome encapsulation overcomes d-type and k-type CpG ODN dichotomy and induces synergistic immune activation = Lipozoma yüklenmiş D-tipi ve K-tipi ODN'lerin sinerjik immun aktivasyonu
(Bilkent University, 2014)Liposomes are one of the best candidates for the encapsulation of labile bioactive agents due to their safety and high entrapment efficiency. In human, two structurally distinct classes of CpG ODN are capable of activating ...
